Please assess the completion status of the following clinical trial:

Trial Title: Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female subjects~* Sterilized by tubal ligation~* Age 18-45 years~* Body mass index (BMI) at screening: ≥ 18 and ≤ 32 kg/m²~* At least 3 consecutive regular menstrual cycles with a cycle length of 24 - 35 days before first screening examination according to the subject's history~* Absence of clinically relevant abnormal findings in the pre-treatment endometrial biopsy~Exclusion Criteria:~* Regular use of medicines (incl. anabolics)~* Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal~* Amenorrhea for more than 3 months within the last 6 months before the first screening examination~* Lacking suitability for frequent transvaginal ultrasonography (TVU) examinations~* Clinically relevant findings (e.g. blood pressure, electrocardiogram \[ECG\], physical and gynecological examination, laboratory examination)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- BAY1002670 [0.1mg] (Type: EXPERIMENTAL): 0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [0.5mg] (Type: EXPERIMENTAL): 0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [1.0mg] (Type: EXPERIMENTAL): 1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [2.0mg] (Type: EXPERIMENTAL): 2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [5.0mg] (Type: EXPERIMENTAL): 5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).